Skip to main content
Sinopharm Group Co. Ltd. logo

Sinopharm Group Co. Ltd. — Investor Relations & Filings

Ticker · 1099 ISIN · CNE100000FN7 LEI · 529900N54X78YH9JYK92 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,610 across all filing types
Latest filing 2024-04-26 Regulatory Filings
Country CN China
Listing HKEX 1099

About Sinopharm Group Co. Ltd.

http://www.sinopharmholding.com

Sinopharm Group Co. Ltd. is a major state-owned enterprise recognized as the largest pharmaceutical logistics provider in Asia and a leading distributor and retailer of healthcare products. The company's core business revolves around providing comprehensive medical supply chain services, encompassing the wholesale and retail distribution of pharmaceuticals, medical devices, and general healthcare products. Sinopharm serves a broad customer base, including hospitals, primary health service institutions, and retail pharmacies. Furthermore, the Group maintains an integrated ecosystem that extends beyond distribution into the manufacturing of pharmaceuticals and chemical reagents, medical services, and industry-finance integration, positioning it as a full-spectrum service provider in the healthcare sector.

Recent filings

Filing Released Lang Actions
Annual Report 2023
Regulatory Filings
2024-04-26 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-04-25 English
ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE FIRST QUARTER ENDED 31 MARCH 2024
Earnings Release Classification · 95% confidence The document is an announcement titled 'PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE FIRST QUARTER ENDED 31 MARCH 2024'. It provides key unaudited financial data for the first quarter ended 31 March 2024, including revenue, net profit, earnings per share, and total assets. The document references compliance with listing rules and is clearly an announcement of financial results for a quarterly period. The length is 4432 characters, which is relatively short and typical for an earnings release announcement rather than a full interim report containing detailed financial statements and analysis. The document does not contain comprehensive financial statements or detailed management discussion and analysis, but rather highlights principal financial data. Therefore, it fits the definition of an Earnings Release (ER) which is an initial announcement of quarterly financial results with key highlights only. Q1 2024
2024-04-25 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-04-25 English
ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE FIRST QUARTER ENDED 31 MARCH 2024
Interim / Quarterly Report Classification · 95% confidence The document is an announcement of principal unaudited accounting data and financial indicators for the first quarter ended 31 March 2024 of Sinopharm Accord, a subsidiary of Sinopharm Group Co. Ltd. It references the first quarter period and provides detailed financial figures such as revenue, net profit, earnings per share, and segment performance. The document is about quarterly financial results with substantive financial data and analysis, not just a brief earnings highlight or a report publication notice. It is not a full annual report but a quarterly financial report with actual financial statements and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (7299 characters) supports it being a substantive report rather than a short announcement or certification. Hence, the classification is IR with high confidence. Q1 2024
2024-04-25 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a notice announcing a forthcoming board meeting scheduled for April 26, 2024, where the board will consider and approve the unaudited quarterly results for the three months ended March 31, 2024. The document does not contain any financial data or results itself, but merely announces the meeting date and agenda. It is a short notice (1535 characters) and fits the pattern of a Regulatory Filing (RNS) as it is a general regulatory announcement about a board meeting and upcoming financial results, not the financial report itself or a detailed management discussion. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-04-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.